151 related articles for article (PubMed ID: 38936665)
1. Biologics and Candidiasis Incidence: Minimally Rising Yeast.
Heymann WR
J Am Acad Dermatol; 2024 Jun; ():. PubMed ID: 38936665
[No Abstract] [Full Text] [Related]
2. Incidence of New-Onset Inflammatory Bowel Disease, Oral and Gastrointestinal Candidiasis, Herpes Zoster, Pulmonary Tuberculosis, and Major Cardiovascular Events in Patients with Moderate-to-Severe Psoriasis Exposed to Biologics.
Kang DH; Lew BL; Kwon SH
J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137722
[TBL] [Abstract][Full Text] [Related]
3. Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources.
Davidson L; van den Reek JMPA; Bruno M; van Hunsel F; Herings RMC; Matzaraki V; Boahen CK; Kumar V; Groenewoud HMM; van de Veerdonk FL; Netea MG; de Jong EMGJ; Kullberg BJ
Lancet Reg Health Eur; 2022 Feb; 13():100266. PubMed ID: 34950923
[TBL] [Abstract][Full Text] [Related]
4. Risk of infections of biological and targeted drugs in patients with spondyloarthritis: meta-analysis of randomized clinical trials.
Hu L; Man S; Ji X; Wang Y; Liu X; Zhang J; Song C; Zhu J; Huang F
Chin Med J (Engl); 2022 Apr; 135(8):911-919. PubMed ID: 35730370
[TBL] [Abstract][Full Text] [Related]
5. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
Wu S; Xu Y; Yang L; Guo L; Jiang X
Front Immunol; 2023; 14():1294416. PubMed ID: 38106423
[TBL] [Abstract][Full Text] [Related]
6. A study of the efficacy and safety of plaque psoriasis treatment by TNF-α and IL-17A inhibitor biologics in patients who received the inactivated SARS-CoV-2 vaccine.
Ye S; Sun H; Xu Z; Xu B; Wu N; Wu J
Immun Inflamm Dis; 2023 Jul; 11(7):e938. PubMed ID: 37506146
[TBL] [Abstract][Full Text] [Related]
7. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
8. Increased susceptibility of TNF-alpha lymphotoxin-alpha double knockout mice to systemic candidiasis through impaired recruitment of neutrophils and phagocytosis of Candida albicans.
Netea MG; van Tits LJ; Curfs JH; Amiot F; Meis JF; van der Meer JW; Kullberg BJ
J Immunol; 1999 Aug; 163(3):1498-505. PubMed ID: 10415052
[TBL] [Abstract][Full Text] [Related]
9. Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management.
Bilal H; Khan MN; Khan S; Fang W; Chang W; Yin B; Song NJ; Liu Z; Zhang D; Yao F; Wang X; Wang Q; Cai L; Hou B; Wang J; Mao C; Liu L; Zeng Y
Mycology; 2024; 15(1):30-44. PubMed ID: 38558839
[TBL] [Abstract][Full Text] [Related]
10. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence.
Sun X; Cui Z; Wang Q; Liu L; Ding X; Wang J; Cai X; Li B; Li X
Autoimmun Rev; 2024 Apr; 23(4):103530. PubMed ID: 38499168
[TBL] [Abstract][Full Text] [Related]
11. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
van der Schoot LS; van den Reek JMPA; Grine L; Schots L; Kievit W; Lambert JLW; de Jong EMGJ
Trials; 2021 Oct; 22(1):707. PubMed ID: 34656148
[TBL] [Abstract][Full Text] [Related]
12. Exogenous farnesol interferes with the normal progression of cytokine expression during candidiasis in a mouse model.
Navarathna DH; Nickerson KW; Duhamel GE; Jerrels TR; Petro TM
Infect Immun; 2007 Aug; 75(8):4006-11. PubMed ID: 17517874
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Treatment Strategies with Biologics in Accordance with Treatment Guidelines for Ankylosing Spondylitis: A Patient-Level Model.
Le QA; Kang JH; Lee S; Delevry D
J Manag Care Spec Pharm; 2020 Oct; 26(10):1219-1231. PubMed ID: 32996395
[TBL] [Abstract][Full Text] [Related]
14. Low incidence of invasive fungal infection and risk factors in a large observational cohort of patients initiating tumor necrosis factor-alpha inhibitors for dermatologic conditions.
Hennessee I; Benedict K; Bahr NC; Lipner SR; Gold JAW
J Am Acad Dermatol; 2024 Apr; ():. PubMed ID: 38685411
[No Abstract] [Full Text] [Related]
15. Biological therapy in Psoriasis: An emphasis on its dermatologic adverse events.
Palakornkitti P; Nimmannitya K; Rattanakaemakorn P
Asian Pac J Allergy Immunol; 2021 Dec; 39(4):215-230. PubMed ID: 34953482
[TBL] [Abstract][Full Text] [Related]
16. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
[TBL] [Abstract][Full Text] [Related]
17. Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
Al-Janabi A; Alabas OA; Yiu ZZN; Foulkes AC; Eyre S; Khan AR; Reynolds NJ; Smith CH; Griffiths CEM; Warren RB;
JAMA Dermatol; 2024 Jan; 160(1):71-79. PubMed ID: 38055239
[TBL] [Abstract][Full Text] [Related]
18. Interleukin inhibitors and the associated risk of candidiasis.
Khan S; Bilal H; Khan MN; Fang W; Chang W; Yin B; Song NJ; Liu Z; Zhang D; Yao F; Wang X; Wang Q; Cai L; Hou B; Wang J; Mao C; Liu L; Zeng Y
Front Immunol; 2024; 15():1372693. PubMed ID: 38605952
[TBL] [Abstract][Full Text] [Related]
19. Effect of biologics in the level of cytokines in the synovial fluid of patients with ankylosing spondylitis.
Koo BS; Jo S; Kwon E; Shin JH; Hur JW; Kim TH
Korean J Intern Med; 2020 Mar; 35(2):465-473. PubMed ID: 31830775
[TBL] [Abstract][Full Text] [Related]
20. Lactobacillus rhamnosus intake can prevent the development of Candidiasis.
Leão MVP; Tavares TAA; Gonçalves E Silva CR; Dos Santos SSF; Junqueira JC; de Oliveira LD; Jorge AOC
Clin Oral Investig; 2018 Sep; 22(7):2511-2518. PubMed ID: 29372447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
